Abstract
Photodynamic therapy has many treatment applications for malignant and premalignant lesions of the skin. The basic principle involves application of a photosensitizer followed by exposure of the target tissues to light. 5-aminolevulinic acid is a natural occurring compound in the heme biosynthesis pathway. Its metabolite protoporphyrin IX is a photosensitizer that has the ability to selectively damage premalignant, malignant, and certain abnormal tissues, rendering its wide application for use in actinic keratosis, Bowen’s disease, and basal cell carcinoma. Adequate lesion preparation is critical for successful treatment. Ongoing research on the clinical use of photodynamic therapy, its potential impact in oncological patient management and on public health and cost is continuously evolving. The perfection of this light therapy on patient treatment awaits results of future clinical trials.
Keywords: Non-melanoma, photodynamic therapy, photosensitizers, skin cancer, treatment.
Current Cancer Therapy Reviews
Title:Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Volume: 12 Issue: 2
Author(s): Edward Yu
Affiliation:
Keywords: Non-melanoma, photodynamic therapy, photosensitizers, skin cancer, treatment.
Abstract: Photodynamic therapy has many treatment applications for malignant and premalignant lesions of the skin. The basic principle involves application of a photosensitizer followed by exposure of the target tissues to light. 5-aminolevulinic acid is a natural occurring compound in the heme biosynthesis pathway. Its metabolite protoporphyrin IX is a photosensitizer that has the ability to selectively damage premalignant, malignant, and certain abnormal tissues, rendering its wide application for use in actinic keratosis, Bowen’s disease, and basal cell carcinoma. Adequate lesion preparation is critical for successful treatment. Ongoing research on the clinical use of photodynamic therapy, its potential impact in oncological patient management and on public health and cost is continuously evolving. The perfection of this light therapy on patient treatment awaits results of future clinical trials.
Export Options
About this article
Cite this article as:
Yu Edward, Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies, Current Cancer Therapy Reviews 2016; 12 (2) . https://dx.doi.org/10.2174/1573394712666160919104726
DOI https://dx.doi.org/10.2174/1573394712666160919104726 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective
Current Molecular Medicine Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature
Recent Patents on Anti-Cancer Drug Discovery Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Dendritic Cell/NK Cell Interaction in RNA Virus Infection
Current Immunology Reviews (Discontinued) <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry